Literature DB >> 18395905

Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers.

Hatsushi Yamagishi1, Tomoyuki Koike, Shuichi Ohara, Toru Horii, Ryousuke Kikuchi, Shigeyuki Kobayashi, Yasuhiko Abe, Katsunori Iijima, Akira Imatani, Kaori Suzuki, Takanori Hishinuma, Junichi Goto, Tooru Shimosegawa.   

Abstract

AIM: To compare rabeprazole (RPZ; 10 mg) with Lansoprazole orally disintegrating tablets (LPZ; 30 mg OD) in terms of antisecretory activity and blood drug concentration after a single dose.
METHODS: Eight H pylori -negative cytochrome P450 (CYP) 2C19 extensive metabolizers were assigned to receive a single oral dose of RPZ 10 mg or LPZ 30 mg OD. Twelve hour intragastric pH monitoring was performed on the day of treatment. Blood samples were also collected after the administration of each drug.
RESULTS: LPZ 30 mg OD induced a significantly earlier rise in blood drug concentration than RPZ 10 mg; consequently, LPZ 30 mg OD induced a significantly earlier rise in median pH in the third and fourth hours of the study.
CONCLUSION: In H pylori-negative CYP2C19 extensive metabolizers, LPZ 30 mg OD induced a significantly faster inhibition of gastric acid secretion than RPZ 10 mg.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395905      PMCID: PMC2701526          DOI: 10.3748/wjg.14.2049

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  46 in total

1.  Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection.

Authors:  J Martínek; A L Blum; M Stolte; M Hartmann; E F Verdú; R Lühmann; G Dorta; P Wiesel
Journal:  Aliment Pharmacol Ther       Date:  1999-01       Impact factor: 8.171

2.  Trends of average intake of macronutrients in 47 prefectures of Japan from 1975 to 1994--possible factors that may bias the trend data.

Authors:  N Yoshiike; Y Matsumura; M Yamaguchi; F Seino; M Kawano; K Inoue; T Furuhata; Y Otani
Journal:  J Epidemiol       Date:  1998-08       Impact factor: 3.211

3.  Lansoprazole quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry.

Authors:  Celso H Oliveira; Rafael E Barrientos-Astigarraga; Eduardo Abib; Gustavo D Mendes; Débora R da Silva; Gilberto de Nucci
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-01-15       Impact factor: 3.205

4.  The role of endoscopic findings for the diagnosis of Helicobacter pylori infection: evaluation in a country with high prevalence of atrophic gastritis.

Authors:  M Mihara; K Haruma; T Kamada; K Komoto; M Yoshihara; K Sumii; G Kajiyama
Journal:  Helicobacter       Date:  1999-03       Impact factor: 5.753

5.  Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

Authors:  N Shirai; T Furuta; Y Moriyama; H Okochi; K Kobayashi; M Takashima; F Xiao; K Kosuge; K Nakagawa; H Hanai; K Chiba; K Ohashi; T Ishizaki
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

6.  Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.

Authors:  A Farley; L D Wruble; T J Humphries
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

7.  Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.

Authors:  Y Horai; M Kimura; H Furuie; K Matsuguma; S Irie; Y Koga; T Nagahama; M Murakami; T Matsui; T Yao; A Urae; T Ishizaki
Journal:  Aliment Pharmacol Ther       Date:  2001-06       Impact factor: 8.171

8.  A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.

Authors:  M P Williams; J Sercombe; M I Hamilton; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1998-11       Impact factor: 8.171

9.  Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.

Authors:  T Saitoh; Y Fukushima; H Otsuka; J Hirakawa; H Mori; T Asano; T Ishikawa; T Katsube; K Ogawa; S Ohkawa
Journal:  Aliment Pharmacol Ther       Date:  2002-10       Impact factor: 8.171

10.  Clinical characteristics of Japanese reflux esophagitis patients as determined by Los Angeles classification.

Authors:  Masahiko Inamori; Jun-Ichi Togawa; Hajime Nagase; Yasunobu Abe; Tadashi Umezawa; Atsushi Nakajima; Toshifumi Saito; Norio Ueno; Katsuaki Tanaka; Hisahiko Sekihara; Hiroki Kaifu; Hideo Tsuboi; Hideyuki Kayama; Shizuo Tominaga; Hiroshi Nagura
Journal:  J Gastroenterol Hepatol       Date:  2003-02       Impact factor: 4.029

View more
  2 in total

1.  Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life.

Authors:  Fuminao Takeshima; Keiichi Hashiguchi; Yasunori Onitsuka; Ken Tanigawa; Hitomi Minami; Kayoko Matsushima; Yuko Akazawa; Ken Shiozawa; Naoyuki Yamaguchi; Naota Taura; Ken Ohnita; Tatsuki Ichikawa; Hajime Isomoto; Kazuhiko Nakao
Journal:  Med Sci Monit       Date:  2015-12-31

2.  A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.

Authors:  Akihito Nagahara; Tsuyoshi Suzuki; Naoyoshi Nagata; Nozomu Sugai; Yoshiaki Takeuchi; Kouichi Sakurai; Masaki Miyamoto; Kazuhiko Inoue; Junichi Akiyama; Katsuhiro Mabe; Ichiro Konuma; Tomoari Kamada; Ken Haruma
Journal:  J Gastroenterol       Date:  2013-12-24       Impact factor: 7.527

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.